

<sup>24</sup>**Background:** Treatment of severely injured patients represents a major challenge, in part 25 due to the unpredictable risk of major adverse events, including death. Preemptive 26 personalized treatment aimed at preventing these events is a key objective of patient 27 management; however, the currently available scoring systems provide only moderate 28 guidance. Molecular biomarkers from proteomics/peptidomics studies hold promise for 29 improving the current situation, ultimately enabling precision medicine based on individual 30 molecular profiles. <sup>31</sup>**Methods:** To test the hypothesis that proteomics biomarkers could predict patient outcomes 32 in severely injured patients, we initiated a pilot study involving consecutive urine sampling <sup>33</sup>(on days 0, 2, 5, 10, and 14) and subsequent peptidome analysis using capillary 34 electrophoresis coupled to mass spectrometry (CE-MS) of 14 severely injured patients and 35 two additional ICU patients. The urine peptidomes of these patients were compared to the 36 urine peptidomes of age- and sex-matched controls. Previously established urinary peptide-

37 based classifiers, CKD274, AKI204, and CoV50, were applied to the obtained peptidome

38 data, and the association of the scores with a combined endpoint (death and/or kidney failure

39 and/or respiratory insufficiency) was investigated.

<sup>40</sup>**Results:** CE-MS peptidome analysis identified 281 peptides that were significantly altered in <sup>41</sup>severely injured patients. Consistent upregulation was observed for peptides from A1AT, 42 FETUA, and MYG, while peptides derived from CD99, PIGR and UROM were consistently 43 reduced. Most of the significant peptides were from different collagens, and the majority were 44 reduced in abundance. Two of the predefined peptidomic classifiers, CKD273 and AKI204, 45 showed significant associations with the combined endpoint, which was not observed for the 46 routine scores generally applied in the clinics.

<sup>47</sup>**Conclusions:** This prospective pilot study confirmed the hypothesis that urinary peptides 48 provide information on patient outcomes and may guide personalized interventions based on 49 individual molecular changes. The results obtained allow the planning of a well-powered 50 prospective trial investigating the value of urinary peptides in this context in more detail.

<sup>51</sup>**Keywords:** urine, biomarker, trauma, polytrauma, intensive care, critical care, proteomics,

52 peptides, prediction

# <sup>53</sup>**Background**

54 Severe trauma patients represent a significant medical challenge, often requiring intensive 55 care unit (ICU) admission due to the life-threatening nature of their injuries (1). These 56 patients have sustained critical injuries, e.g., car accidents, high-energy trauma or falls from 57 great heights(2). Managing severely injured patients in the ICU involves a multidisciplinary 58 approach(3). The outcome of these patients can be unpredictable given the severity of their 59 injuries(4). Often, despite intensive monitoring and intervention, their condition can <sup>60</sup>deteriorate significantly, become unsustainable, and ultimately result in death due to multiple 61 organ dysfunction syndrome (MODS)(5). <sup>62</sup>When referring to polytraumatized patients, the definition by Muhr and Tscherne is frequently 63 applied (6). However, the term 'polytrauma' is used inconsistently. Therefore, a new definition 64 of polytrauma was recently developed(7). Today, the widely accepted definition, the New <sup>65</sup>Berlin Score, characterizes polytrauma as a significant injury in at least 2 body regions with <sup>66</sup>an abbreviated injury scale (AIS) score of 3 or higher and at least one pathological value for 67 one of the following parameters: age (above 70), hypotension (systolic blood pressure <90 68 mmHg), unconsciousness (Glasgow coma scale (GCS) at the scene  $\leq=8$ ), acidosis (base 69 excess  $\leq$ =-6), and coagulopathy (partial thromboplastin time (PTT) >=40/INR >=1.4)(7). <sup>70</sup>Similarly, the definition of 'multiorgan failure' (MOF) has evolved. MOF was redefined in 1992 71 through a consensus conference(8). MOF was no longer defined as a static condition but 72 rather a dynamic and reversible process. Additionally, the classical MOF was replaced with <sup>73</sup>MODS and comprehensively defined. In this definition, MODS is described as the 74 dysfunction of organs in critically ill patients, which can only be resolved through therapeutic

75 interventions(8).



101 are widely used. The ISS is calculated by adding the three highest body area values of the

102 abbreviated injury scale (AIS) squared together(14). The TRISS, introduced in 1981, is a

103 combined index based on the revised trauma score (RTS), ISS, and patient age to predict 104 survival probabilities(14). The results indicate that the TRISS aligns well with expected 105 outcomes and performs favourably compared to other indices, such as the ISS(14). 106 However, these variables may not capture the full complexity of a patient's condition. 107 The revised injury severity classification (RISC) score, introduced in 2003, included not only 108 anatomical injury descriptions but also physiological indicators (e.g., base deficit, 109 haemoglobin, and cardiopulmonary resuscitation)(15). To address some remaining issues, 110 accompanied by the RISC score, the RISC II was developed(15). In addition to other 111 changes, it includes new predictors such as pupil size and reactivity . The RISC-II model 112 outperforms the original RISC, particularly in terms of discrimination, precision, and 113 calibration. It can be used to estimate the risk of death in severely injured patients more <sup>114</sup>effectively. The integration of RISC II into daily intensive care practice, especially as a tool for 115 monitoring patient progress, is challenging due to its complex calculation and the collection 116 of numerous parameters(15,16). 117 In the context of ICU management, advanced laboratory testing and monitoring are crucial. 118 Parameters such as N-terminal pro B-Typ natriuretic peptide (NT-proBNP) and troponin are 119 used to assess cardiac function(17). However, there is a known mutual influence of these 120 parameters in cases of concurrent kidney failure, prompting more recent literature to 121 emphasize more recent, independent markers such as B-type natriuretic peptide. <sup>122</sup>The emergence of "-omics" approaches, including proteomics and genomics, has potential 123 for improved prediction and treatment strategies in trauma care. Changes in urine peptide 124 patterns can provide valid insights into several organ systems (18,19). Biomarkers such as 125 AKI204, which is useful for predicting acute kidney injury (AKI) in ICU patients (20), and 126 CKD273, which is a biomarker for the detection of chronic kidney disease (CKD), can predict

<sup>127</sup>worsening of kidney function (21) or cardiovascular outcome (22) and may be good

128 biomarkers for both predicting kidney damage in polytraumatized patients and providing the

129 time to start renal replacement therapy early (23,24). The COV50 classifier, developed

130 during the COVID-19 pandemic was able to predict the incidence of death and disease

131 progression in infected patients (25). It also demonstrated significant prediction of mortality in

- 132 patients without SARS-CoV-2 infection in the ICU but also in the general population (25,26).
- 133 These results support the hypothesis that urinary peptide-based biomarker classifiers
- 134 represent a significant advancement in the ability to monitor and manage complex
- 135 pathophysiological processes in polytraumatized patients. Therefore, the aims of this pilot
- 136 study were to examine whether trauma-specific peptides can be identified in urine samples
- 137 and whether urinary peptide-based classifiers may predict patient outcomes and organ
- 138 failure.

# <sup>139</sup>**Methods**

### <sup>140</sup>*Cohort description*

141 In this prospective nonrandomized pilot study, urinary proteomic data from 16 severely

142 injured patients recruited between January and July 2023 were examined. All adult patients

143 aged >18 years of both genders who had experienced primary trauma and were admitted to

144 our level 1 trauma center were included. Patients with direct traumatic consequences to the

145 urinary tract, bladder, or kidneys were excluded due to unpredictable analysis failure.

146 Treatment followed the current state of medical practice, in accordance with guidelines and

147 international standards.

<sup>148</sup>Each patient was informed about the study and the procedure either immediately or after 149 regaining consciousness and capacity. In the case of a caregiver situation, the caregiver was 150 provided with appropriate information. Informed consent was obtained retrospectively once a 151 caregiver was available or the capacity for consent was established. If retrospective inclusion 152 in the study was undesirable, the patient's collected data were excluded. All participants 153 provided written consent, and the study was approved by the Ethics Committee of Hannover 154 Medical School (No: 10415\_BO\_S\_2022).

155 The study was conducted in accordance with Good Clinical Practice and the Declaration of

- 156 Helsinki. According to the New Berlin score, 14 of the 16 patients met the criteria for
- 157 polytrauma (19). These multiple-injury patients had an ISS  $\geq$  16, at least two injuries with an
- 158 AIS of ≥ 3 and an indication for intensive care monitoring or surgery. The other two patients
- 159 had a single injury requiring a longer hospital stay (e.g. vacuum sealing, external fixator,
- 160 extensive soft tissue damage) ensuring that the entire monitoring period was completed.

### <sup>161</sup>*Urine sample and data collection*

- <sup>162</sup>For all 16 patients, urine samples and data were collected in the department of Trauma
- 163 Surgery, Medical School of Hanover, Hanover, Germany. If a urinary catheter was inserted in
- 164 the emergency room, the first urine sample was collected, as shown in the flow diagram
- <sup>165</sup>(**Figure 1**). Blood was also sampled according to polytrauma standards. If patients were
- 166 directly admitted to the intensive care unit following admission to the emergency room, the
- 167 first urine sample was collected. According to the study design, urine was sampled on days
- <sup>168</sup>0, 2, 5, 10, and 14 using a urine monovette containing boric acid (Sarstedt, Nümbrecht,
- 169 Germany) and stored frozen at -20 $^{\circ}$ C.
- <sup>170</sup>*Figure 1: Collection of urine and blood samples and scoring*



#### <sup>172</sup>*Parameters*

173 On the days of urine collection, the patients were assessed using current intensive care

174 scores. On the day of admission, the ISS, TRISS, RISC II, APACHE-II, SAPS-II, and TIPS

175 scores were recorded. Since the extent of injury did not change, the ISS and TRISS were

176 only recorded at admission. APACHE-II was scored analogously on all sampling days, while

177 SAPS-II and TIPS were assessed once upon admission.

178 Blood samples were also taken on the sampling days. The samples were investigated for

179 electrolytes, lactate, CRP, complete blood count with haemoglobin and leukocytes,

180 coagulation parameters (INR, PTT), and kidney retention parameters.

181 Furthermore, the following events were recorded: Long-term ventilation, tracheotomy, prone

182 position, acute respiratory distress syndrome (ARDS), acute kidney failure, dialysis,

183 cardiovascular events, resuscitation, death, emergency surgery, extracorporeal membrane

<sup>184</sup>oxygenation (ECMO), and early discharge from the ICU (**Supplementary Table 1**). The

185 combined endpoint was defined as death and/or kidney failure and/or respiratory

186 insufficiency.

#### <sup>187</sup>*Proteomic analysis and data processing*

188 Urine sample preparation was performed as previously described (27). Briefly, the urine 189 samples were thawed immediately before use, and 0.1 ml of urine was diluted with 0.7 ml of 190 2 M urea and 10 mM NH4OH containing 0.02% SDS. The samples were ultrafiltered and 191 desalted using a PD-10 column (GE Healthcare, Danderyd, Sweden) equilibrated with 0.01% 192 NH4OH. The filtrate was lyophilized and stored at 4°C until Capillary electrophoresis–mass 193 spectrometry (CE-MS) analysis was performed. CE-MS analyses were performed on a <sup>194</sup>P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Brea, California) coupled 195 on-line to a micrOTOF II mass spectrometer (Bruker Daltonic, Bremen, Germany) as 196 previously described (28).

<sup>197</sup>The mass spectral peaks were deconvoluted using MosaFinder software (29). Normalization

<sup>198</sup>was performed using a linear regression algorithm with internal standard peptides as

199 references. The detected peptides were deposited, matched, and annotated in the Microsoft

200 SQL database (Microsoft, Redmond, Washington, USA).

201 The amino acid sequences were obtained by performing MS/MS analysis using a P/ACE CE

202 coupled to a Q Exactive™ Plus Hybrid Quadrupole-Orbitrap™ MS instrument (Thermo

203 Fisher Scientific, Waltham, Massachusetts, USA). The mass spectrometer was operated in

204 data-dependent mode to automatically switch between MS and MS/MS acquisition. The data

205 files were searched against the UniProt human nonredundant database using Proteome

206 Discoverer 2.4 and the SEQUEST search engine without enzyme specification (activation

207 type: HCD; precursor mass tolerance: 5 ppm); fragment mass tolerance: 0.05 Da). The false

208 discovery rate (FDR) was set to 1%. For further validation of the obtained peptide

209 sequences, the correlation between peptide charge at a working pH of 2 and CE migration

210 time was used to minimize false-positive derivation rates (30). The calculated CE migration

- 211 times of the sequence candidates based on their peptide sequences (number of basic amino
- 212 acids) were compared to the experimental migration times.

#### <sup>213</sup>*Application of urine peptide-based biomarker classifiers*

- 214 In this study, predefined urinary peptide-based classifiers for predicting the onset and
- 215 progression of CKD, AKI, and ARDS were used. For testing the endpoints, the classifiers
- 216 CKD273, AKI204, and Cov50 were applied. previously(19,20,31).

#### <sup>217</sup>*Statistics*

- 218 Statistical analysis was performed using SPSS computer software (SPSS 28, IBM, Armonk,
- 219 New York, USA). Demographics, clinical variables, and proteomics classification scores are
- 220 summarized as the means $\pm$ SDs, and categorical variables are presented as frequencies (%).
- 221 Group means were compared using the Wilcoxon rank sum exact test, Fisher's exact test
- 222 and Wilcoxon rank sum test.
- 223 The CE-MS-based data of 14 trauma patients and 14 sex- and age-matched healthy controls
- 224 extracted from the human urinary databasewere used to identify urinary peptides potentially
- 225 associated with trauma (29). The statistical analysis was performed using R-based statistical
- 226 software. Only peptides with a frequency threshold of at least 70% in one of the groups were
- 227 considered. P values were obtained using the Wilcoxon signed-rank test, followed by
- 228 Benjamini–Hochberg false discovery rate adjustment.

# <sup>229</sup>**Results**

### <sup>230</sup>*Cohort characteristics*

- 231 The patient characteristics of the whole cohort (n=16) are shown in **Table 1**. The average
- 232 age of the study population was  $46 \pm 21$  years. The mean ISS was 27  $\pm$  15, the average
- <sup>233</sup>TRISS was 56 ± 39, and the average RISC II score was 11±14. In **Table 2** mean AIS,
- 234 systolic blood pressure and ASA score (classification of patients regarding their physical

235.	condition, American Society of Anesthesiologists) of the 14 polytraumatized patients are
236	shown. The mean AIS for the head, face, thorax, abdomen, extremities with pelvic injuries
237	and external injuries were 2.00±1.24, 0.64±0.84, 2.64±1.65, 2.00±1.74, 2.50±1.40 and
238	0.93±0,83, respectively, at admission. The mean systolic blood pressure was 133.93
239	mmHg±17.67 at admission. The average preclinical ASA score was 1.43. Upon admission,
240	the average SAPS II score was $32$ ( $\pm$ 13), and the average TIPS score was 17.54 ( $\pm$ 9.46).

<sup>241</sup>*Table 1: Mean values for baseline cohort characteristics of all 16 patients included (14 polytrauma patients),* 

<sup>242</sup>*EP EP = Endpoint,* \**Wilcoxon rank sum exact test; Fisher's exact test; Wilcoxon rank sum test* 



<sup>244</sup>*Table 2: Mean values for AIS, systolic bloodpressure and ASA of all 14 polytraumatzed patients* 

<b>Characteristics</b>		mean	SD
Abbrevieated Injury Scale (AIS)	14	2,00	1.24



<sup>245</sup>*Trauma patient outcomes* 

<sup>246</sup>**Supplementary Table 1** lists the frequencies of injuries and recorded events during the 14- 247 day monitoring period in the polytrauma patients  $(n=14)$ . Eleven patients suffered from 248 traumatic brain injury (n=11), while one patients had spinal cord injury. Thoracic trauma was 249 present in 71% of the patients ( $n=10$ ), and half of the patients had both abdominal trauma 250 (n=7) and pelvic injuries (n=7). The following events were observed during the study: 1 251 patient did not survive the study (7%). Four patients developed respiratory insufficiency <sup>252</sup>(29%), and an equal number of patients suffered acute kidney failure (29%), with 1 patient 253 requiring dialysis. ECMO support was necessary for one patient (7%). Additionally, one 254 patient needed to be placed in the prone position during intensive care (7%). ARDS 255 developed in 1 patient (7%). **Supplementary Table 2** shows the frequencies of successful 256 probe collection, score and bloodsample trends over the whole monitoring period of 14 days. 257 During the monitoring period, not all urine samples could be collected due to early discharge. 258 Eight patients completed the entire study in 14 days (57%). Despite early discharge and the 259 reduction in the number of patients from the third sampling point (Day 5), the average 260 APACHE II score showed no consistent trend over time (12.3 ±7.6, 11.2 ±6.0, 10.9 ±6.2, 12.1  $261 \pm 6.2$ , 12.6  $\pm 6.6$ ). In the laboratory results corresponding to the sampling days, the highest 262 average lactate levels were observed on the day of admission (2.8 mmol/l  $\pm$ 1.9). 263 Subsequently, there was a successive decrease, with normalization of the lactate levels on 264 the following sampling days (1.6 mmol/l  $\pm$ 1.6, 1.0 mmol/l  $\pm$ 0.4, 0.8 mmol/l  $\pm$ 0.3, 0.7 mmol/l  $265 \pm 0.1$ ).

266 On average, all included patients had normal CRP levels at admission  $(3.2 \text{ mg/dl } \pm 1.9)$ . At 267 sampling days 2 and 4, increases in the average values of 1695 mg/dl  $±99.46$  and 139.0 268  $mg/dl \pm 166.64$ , respectively, were observed.

269 On the day of admission, the patients had an average Hb level of 11.7 g/dl  $\pm$ 2.7, which

- 270 showed the greatest decrease at sampling day 2 (9.1 g/dl  $\pm$ 2.2) and then a successive mild
- 271 decline at the remaining sampling days (9.0 g/dl  $\pm$ 1.7, 8.3 g/dl  $\pm$ 1.3, 8.9 g/dl  $\pm$ 0.9). During the
- 272 monitoring period, 3 patients did not require any packed red blood cells (PRBC) (21%), 1
- 273 patient received 4 PRBCs (7%), 4 patients each received 5 (29%), 2 patients required 7
- <sup>274</sup>(14%), another 2 patients received 12 (14%), and one patient required 36 while another
- 275 needed 57 PRBCs (7%).

### <sup>276</sup>*Definition of urinary peptides specific for polytrauma patients*

277 For the definition of urinary peptides significantly associated with trauma, the urinary peptide 278 data of 14 polytraumatized patients and 14 age- and sex-matched healthy controls from the 279 Human Urinary Peptide Database were used(32). This comparison revealed that 281 280 peptides were significantly affected ( $p<0.05$ , Wilcoxon test followed by adjustment for 281 multiple comparisons by Benjamini and Hochberg). All the identified peptides are listed in <sup>282</sup>**Supplementary Table 3**. We observed consistent upregulation of the expression of the 283 peptides Alpha-1-antitrypsin (A1AT) (n=3), Fetuin (FETUA) (n=3), and Myoglobin (MYG) 284 (n=2), which is in line with expectations and downregulation of the expression of fragments of 285 CD99 (n=9), PIGR (n=9) and UROM (n=6). One highly upregulated ProSAAS fragment was 286 also detected. Most of the significant peptides were fragments of different collagens (n=205), 287 118 of which were downregulated.

### <sup>288</sup>*Application of urinary peptide-based classifiers and their*

### <sup>289</sup>*association with established severity scores*

- 290 On the obtained CE-MS data, the previously developed classifiers CKD273, AKI204 and
- 291 CoV50 were applied. For each classifier and patient, the numeric classification score was
- 292 calculated.
- 293 The classifier for CKD prediction, CKD273, demonstrated a significant correlation with the
- 294 ISS ( $p=0.034$ ) and the APACHE-II score ( $p<0.001$ ). The APACHE-II score was the only
- 295 severity score that was obtained not only at baseline but also at every follow-up timepoint.
- 296 The AKI204 classifier correlated significantly ( $p=0.031$ ) with the SAPS and APACHE-II score
- 297 (p<0.001). The Cov50 classifier was significantly correlated with the ISS (p=0.042), the RISC
- 298 II (p=0.040) and the APACHE-II score (p<0.001). A chart of the correlation statistics is shown
- <sup>299</sup>in **Figure 2**.
- <sup>300</sup>*Figure 2: Chart of correlation statistics between the clinical parameters, severity scores and peptide-based*
- <sup>301</sup>*classifiers.*



302

### <sup>303</sup>*Associations of the parameters with the combined endpoint*

- 304 In the next step, the associations of clinical parameters, severity scores, and the obtained
- 305 peptide-based classification scores at baseline with the combined endpoint were
- 306 investigated. The results are listed in Table 1 and shown in the form of box-whisker plots in
- <sup>307</sup>**Figure 3**. Significant differences between the patients who reached the combined endpoint
- 308 and those who did not were observed for CKD273 and AKI204 ( $p= 0.004$  and  $p= 0.029$ ),
- 309 where the Cov50 classifier showed only a trend  $(p=0.094)$ . The clinical parameters and
- 310 severity scores did not significantly differ between the groups. **Figure 4** displays the
- 311 classification scores of the peptide-based classifiers throughout the entire study period.







<sup>314</sup>*Box-whisker plots of the baseline parameters and their associations with the prediction of the combined endpoint* 

316

317

<sup>315</sup>*(EP) are shown.* 

318

- <sup>319</sup>*Figure 4: Distribution of classification scores obtained using the urinary peptide-based classifiers AKI204,*
- <sup>320</sup>*CKD273, and Cov50 between patients who reached the combined endpoint and those who did not throughout the*
- <sup>321</sup>*entire study duration.*



322

# <sup>323</sup>**Discussion**

- 324 The aim of this study was to investigate whether
- 325 a) severely injured trauma patients exhibit significant deregulation of urinary peptides, and
- 326 b) such changes can be used to predict outcomes and guide treatment.
- 327 The combined endpoints of the patients in this study were defined as death and/or kidney
- 328 failure and/or respiratory insufficiency.
- 329 As hypothesized, our data demonstrated a highly significant deregulation of urinary proteom
- 330 levels in trauma patients. A significant change was observed in CKD273 ( $p = 0.004$ ) and in
- 331 AKI\_204 ( $p = 0.029$ ). Cov50 showed a weak trend ( $p = 0.094$ ).
- <sup>332</sup>These urine proteomes were initially used for predicting acute or acute-on-chronic kidney
- 333 failure (AKI\_207, CKD237) and the development of adverse outcomes in COVID-19 patients
- <sup>334</sup>(Cov50) (20-22,33-35). Only one patient (7,1%) developed ARDS in this small cohort, which
- 335 could explain the non-significant trend in Cov50 ( $p = 0.094$ ). In contrast, four patients
- 336 experienced acute kidney failure, and one patient required dialysis

337 Overall, 281 deregulated peptides were observed among the polytrauma patients. Among 338 the measured peptides, the most notable changes were observed in collagen peptides <sup>339</sup>(**Supplementary Table 3**). This was expected, as collagen peptides are the most abundant 340 peptides in urine and are influenced by several pathologies, including kidney and 341 cardiovascular diseases, as well as death (30). As shown here, the effect on collagen 342 peptides was inconsistent across these pathologies; some peptides were significantly <sup>343</sup>upregulated, while others were highly significantly and consistently reduced(**Supplementary**  <sup>344</sup>**Table 3**). Although these peptides are very common, the molecular mechanisms underlying

### <sup>346</sup>*Kidney failure:*

<sup>347</sup>Alpha-1-antitrypsin and Fetuin showed significant deregulations (**Supplementary Table 3**).

<sup>348</sup>Similar changes have been observed previously in patients with chronic or acute kidney

349 diseases, likely indicating severe renal stress in trauma patients (22,28,33). Stress or

350 damage to the kidney is further indicated by the consistent reduction of uromodulin

345 their regulation and their connection to (patho)physiology remain unknown.

351 fragments (36). Additional consistent and prominent changes include the reduction of

352 fragments of CD99 and the polymeric immunoglobulin receptor (37). Such changes have

353 also been observed in connection with severe/lethal courses of COVID-19 and have been

354 interpreted as possible indications of endothelial damage (30,34-37).

355 There are numerous efforts to predict acute kidney injury in both medically ill and severely 356 injured patients(38). Many functional tests aim to make predictions not through the 357 quantification of laboratory chemical parameters, but through the performance of urine output 358 after stress tests, such as the furosemide stress test or renal functional reserve(38). The 359 standardized furosemide stress test has a good predictive probability (AUC  $0.87$ , p = 0.001) 360 in a limited test group, but the testing requires a coordinated timing of furosemide 361 administration and documentation of time and urine output(39). This must be accommodated 362 within the time-intensive care of critically ill patients(40).

363 Genetic variations as determinants for both risk and outcome are not well defined(41). <sup>364</sup>Association studies have identified a large number of genetic polymorphisms that are 365 capable of predicting different and variable kidney responses to the same type of injury(41). <sup>366</sup>However, identifying these individual genetic susceptibilities for AKI plays no role in 367 managing acute courses in previously healthy, severely injured patients, or in prognostic 368 assessment and therapy timing. Overall, the results of such models are variable and often 369 inconsistent. The lack of robust and reproducible associations with AKI is not surprising given 370 the complex, multifactorial nature of chronic and acute renal insufficiency(38). None of these 371 studies combined the prognostic information from potential genetic polymorphisms with 372 existing prediction models(38). Ideal models for such clinical studies continue to be applied in 373 elective cardiac surgery(42). The reason for this is that cardiac surgical procedures not only 374 represent a large surgical population but also have a well-studied epidemiology of AKI in this 375 context, due to the use of heart-lung machines and the resultant potential ischemia- $376$  reperfusion injury to the kidney(42). However, this population cannot in any way reflect 377 patients who suffer not only massive musculoskeletal damage but also direct injuries to the 378 kidney

379 Severely injured patients with preclinical shock due to hemorrhage and extensive extremity 380 trauma with muscle damage often suffer from kidney damage, which frequently leads to 381 acute renal failure requiring dialysis (43). The need for a predictive tool is substantial, as the 382 prediction and estimation of interventions such as dialysis in the daily routine of intensive 383 care are not currently predicted by injury or mortality scores (ISS, TRISS, RISC II) or by 384 progression assessments such as the APACHE II score. These outcomes still depend on the 385 rapid detection of the condition and the continuous, rigorous monitoring of patients (44).

386 In our patient cohort, 4 patients (29%) showed acute kidney injury. This pilot study showed a 387 significant prediction probability for the development of acute kidney injury in polytraumatized 388 patients  $[CKD273 (p = 0.004)$  and AKI 204 (p = 0.029)].

### *ARDS:*



413 extensive lung damage, similar to what is seen in ARDS(48). Although there are similar

<sup>414</sup>expressions in both diseases, the pathophysiology of COVID-19 differs from ARDS due to its 415 diverse complexity(48,49).



425 aspects, they do have similarities. Especially through the development of ARDS in severe

426 Covid cases, these adverse outcomes can be identified by the urinary proteomic COV50

427 marker. In our study, out of 10 (71,4%) patients with thoracic trauma, 4 developed respiratory

428 insufficiency (28,6%), of which only one patient manifested ARDS (7,1). The COV50 showed

429 only a trend in predicting these endpoint ( $p = 0.094$ ). To better assess the suitability of this

430 urinary proteome, a larger number of patients need to be included compared to this pilot 431 study.

<sup>432</sup>Due to the small number of patients and low manifestation of ARDS at the time of the pilot 433 study, no reliable statements could be made for prognostic assessment, treatment 434 interventions, and intervention timing, such as determining when ECMO (7,1%) or prone 435 positioning (7,1%) is temporally indicated. Nevertheless, considering the trend of COV50 436 alongside other proteomic results, it appears to be a promising avenue to address these 437 exact issues in the management of severe ARDS cases.

<sup>438</sup>*Scores:* 

439 The ISS is calculated by squaring the three highest values of the AIS and then adding them 440 together (56). It is used to quantify and assess the overall injury severity of a patient based 441 on injuries in different body regions (56). However, the ability to determine injury severity 442 based on the discriminative abilities of an ISS threshold depends on a reproducible definition 443 of "severe" (57). The ISS is highly dependent on the person collecting the data (58). <sup>444</sup>Experienced individuals have recorded significantly higher values (58). This inter-observer 445 variability often makes the score's interpretation challenging and less explicit. Evaluating the 446 severity of an injury (i.e., direct acute impact, excluding effects of comorbidities, <sup>447</sup>complications, and treatments) depends on the specific aspects of the illness being 448 considered (57). This evaluation can involve various parameters, such as the likelihood of 449 death, the complexity and extent of required treatments and resources, the probability and 450 degree of permanent impairment, and the impact on the patient's quality of life (57). 451 Accordingly, in this study, we see no significant prediction of an endpoint by the ISS ( $p =$ <sup>452</sup>0.3). The TRISS optimizes the prediction probability and, as a combination score of the RTS 453 and ISS, provides a probability of survival (59). Although historical literature shows alignment 454 with expected predictions, our study found no significance in predicting any endpoint ( $p =$ 455 0.2). There is also criticism of the score, as the variables may not capture the full complexity 456 of the patient's condition (60).

<sup>457</sup>Another approach to improving the prediction of survival probability in polytraumatized 458 patients is the RISC II, which includes not only anatomical injury descriptions but also <sup>459</sup>(patho)physiological indicators (26,57). By incorporating these discriminators, the score aims 460 to estimate the risk of death in severely injured patients more effectively (26). Integrating the 461 RISC II into daily intensive care practice, especially as a tool for monitoring the course of the 462 disease, is significantly challenging due to its difficult accessibility and determination, as the 463 score is primarily designed for initial survival probability assessment (26). Table 1 also shows 464 no significant prediction probability for the endpoints with the RISC II ( $p = 0,4$ ).

465 Scores specifically designed and expanded for the intensive care unit promise better <sup>466</sup>predictive accuracy for critical courses. The APACHE II score, in addition to parameters from <sup>467</sup>individual organ systems, incorporates age, current clinical findings, and medical history to 468 provide a scoring system for assessing critically ill patients, allowing daily predictions about <sup>469</sup>survival probability (1,17,60). Neither on the first day nor throughout the entire sampling 470 period did the APACHE II score show a significant predictive accuracy for any endpoint in 471 this study ( $p = 0.4$ ) (Table 1, Figure 3).

472 The SAPS II provides an assessment of the risk of death and is a tool for predicting the 473 intensive care trajectory of critically ill patients (13). The primary admission diagnosis does 474 not need to be entere (13). The severity of multiple injuries does not influence the predictive 475 accuracy (13). This is confirmed in our research question. The SAPS II score shows no 476 significance in predicting the endpoint ( $p = 0.7$ ). These results are in line to other 477 retrospective multicenter studies, stating the APACHE II score and the SAPS II score did not 478 show acceptable performance in predicting outcomes for intensive care trauma patients (60). 479 Only the APACHE III score was reliable and is still frequently used in daily intensive care 480 medicine (61). However, the score requires additional software support that compares the 481 entered data with historical benchmark data from U.S. hospitals (61).

<sup>482</sup>In our pilot study, none of the established scores showed a significant association with the 483 combined endpoint. This is likely due to the limited power of the study. However, two of the 484 urinary peptide classifiers, AKI204 and CKD273, significantly predicted the outcome ( $p =$ 485  $0.029$ ,  $p = 0.004$ ).

486 Nevertheless, these scores are a gold standard in their respective areas of use and are 487 employed daily in the assessment and care of severely injured and critically ill intensive care 488 patients. In addition to predicting acute kidney injury, CKD273 significantly correlates with the 489 ISS and its associated assessment of the severity of patients' injuries ( $p = 0.034$ ). Likewise, 490 CKD273 shows a correlation with the APACHE II-Score, which was the only score collected

491 at all sampling points and provides an estimate of the progression ( $p < 0.001$ ). AKI 207 also 492 showed a significant correlation with scores for the assessment of intensive care patients 493 and their progression. The classifier correlated with the SAPS II ( $p = 0.031$ ) and the APACHE 494 II score ( $p < 0.001$ ) and could provide an outlook on the intensive care course and care 495 requirements. Similar to CKD273, Cov50 also showed a significant correlation with the ISS (p 496 = 0.042), as well as with the RISC II ( $p = 0.040$ ) and the APACHE II-Score ( $p < 0.001$ ). Thus, <sup>497</sup>Cov50 could also serve as a classifier for the primary assessment of injury severity and the 498 resulting mortality risk.

### <sup>499</sup>*Limitations:*

500 This study has several limitations. First, the sample size was small, with a total of 16 patients 501 and only 14 with polytrauma; thus, this study was designed as a pilot study. Additionally, the 502 complete set of samples (14 days, 5 samples per patient) could only be collected from 8 503 patients. Furthermore, there were some heterogeneous samples. Due to the small number of 504 patients, the study population exhibited a highly heterogeneous pattern of injuries and injury 505 severity. Furthermore, not all relevant laboratory values could be collected on all sampling 506 days. Additionally, there are challenges in data collection once patients are transferred from 507 the ICU to the general ward.

## <sup>508</sup>**Conclusion**

509 The prediction of severe organ damage/organ failure and their critical courses in severely 510 injured patients is still associated with high uncertainty due to individual patterns of injury and 511 progression. The prediction of these events is frequently based on the expertise and 512 experience of the intensivist, with frequent laboratory tests and close monitoring of important 513 organ systems, such as the liver, kidneys, heart, and lungs, required to prepare for 514 unexpected courses and indications for interventions. Nonetheless, intensive care physicians 515 are often faced with unforeseen developments.

- 516 This pilot study should serve as a proof of concept for applying proteome analysis in
- 517 traumatology, paving the way for a multicenter study, as a significantly greater number of
- 518 cases is required for a conclusive evaluation of the investigated biomarkers.

### <sup>519</sup>*List of abbreviations*

- 520 AIS Abbreviated injury scale
- 521 AKI acute kidney injury
- 522 APACHE II acute physiology and chronic health evaluation II
- 523 ARDS acute respiratory distress syndrome
- 524 CE-MS Capillary electrophoresis–mass spectrometry
- 525 CKD Chronic kidney disease
- 526 CRP C-Reaktive Protein
- 527 ECMO extracorporeal membrane oxygenation
- 528 FDR false discovery rate
- 529 GCS Glasgow coma scale
- 530 Hb Haemoglobin
- 531 ICU intensive care unit
- 532 ISS injury severity score
- 533 MODS multiple organ dysfunction syndrome
- 534 MOD multiorgan dysfunction
- 535 MOF multiorgan failure
- 536 SOFA sequential organ failure assessment
- 537 NT-proBNP N-terminal prohormone of brain natriuretic peptide<br>24

- 538 PRBCs packed red blood cells
- 539 PTT partial thromboplastin time
- 540 RISC revised injury severity classification
- 541 RTS revised trauma score
- 542 SAPS II simplified acute physiology score
- 543 TISS therapeutic intervention scoring system
- 544 TRISS trauma and injury severity score

# <sup>546</sup>**References**

- 547 (1) Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score—development, utility
- 548 and challenges of accurate assessment in clinical trials. Critical Care 2019 Nov

<sup>549</sup>27,;23(1):374.

- <sup>550</sup>(2) Balogh ZJ. Polytrauma: It is a disease. Injury 2022 Jun;53(6):1727-1729.
- 551 (3) Rossaint R, Afshari A, Bouillon B, Cerny V, Cimpoesu D, Curry N, et al. The European
- 552 guideline on management of major bleeding and coagulopathy following trauma: sixth
- 553 edition. Critical care (London, England) 2023 Mar 1,;27(1):80.
- <sup>554</sup>(4) van Breugel JMM, Niemeyer MJS, Houwert RM, Groenwold RHH, Leenen LPH, van
- <sup>555</sup>Wessem KJP. Global changes in mortality rates in polytrauma patients admitted to the ICU-a
- 556 systematic review. World journal of emergency surgery 2020 Sep 30,;15(1):55.
- <sup>557</sup>(5) Hutchings L, Watkinson P, Young JD, Willett K. Defining multiple organ failure after major
- 558 trauma: A comparison of the Denver, Sequential Organ Failure Assessment, and Marshall
- 559 scoring systems. The journal of trauma and acute care surgery 2017 Mar;82(3):534-541.

- <sup>560</sup>(6) Kroupa J. Definition of "polytrauma" and "polytraumatism". Acta chirurgiae orthopaedicae
- 561 et traumatologiae Čechoslovaca 1990 July;57(4):347-360.
- <sup>562</sup>(7) Lichte P, Lefering R, Marzi I, Bouillon B, Peitzman A, Balogh Z, et al. Neudefinition des
- 563 Polytraumas ("Berlin Definition") anhand des Traumaregister DGU® Ergebnis eines
- 564 internationalen Konsensprozesses. 2014 Oct 13,.
- <sup>565</sup>(8) Cohen IL. Definitions for Sepsis and Organ Failure: The ACCP/SCCM Consensus
- 566 Conference Committee Report. 1993 Feb 1,;103(2):656.
- <sup>567</sup>(9) Sauaia A, Moore EE, Johnson JL, Chin TL, Banerjee A, Sperry JL, et al. Temporal trends
- 568 of postinjury multiple-organ failure: still resource intensive, morbid, and lethal. 2014
- 569 Mar;76(3):582-593.
- 570 (10) Cole E, Gillespie S, Vulliamy P, Brohi K, Akkad H, Apostolidou K, et al. Multiple organ
- 571 dysfunction after trauma. 2020 Mar;107(4):402-412.
- 572 (11) ZYGUN DA, LAUPLAND KB, FICK GH, SANDHAM JD, DOIG CJ. Limited ability of
- 573 SOFA and MOD scores to discriminate outcome : a prospective evaluation in 1,436 patients.
- 574 2005 Mar 1,;52(3):302-308.
- <sup>575</sup>(12) KNAUS WA, DRAPER EA, WAGNER DP, ZIMMERMAN JE. APACHE II: A severity of
- 576 disease classification system. 1985 Oct;13(10):818-829.
- 577 (13) Le Gall JR. A new Simplified Acute Physiology Score (SAPS II) based on a
- <sup>578</sup>European/North American multicenter study. 1993 Dec 22,;270(24):2957-2963.
- <sup>579</sup>(14) Singh J, Gupta G, Garg R, Gupta A. Evaluation of trauma and prediction of outcome
- 580 using TRISS method. 2011 Oct;4(4):446-449.

- 581 (15) Lefering R, Huber-Wagner S, Nienaber U, Maegele M, Bouillon B. Update of the trauma
- 582 risk adjustment model of the TraumaRegister DGU™: the Revised Injury Severity
- 583 Classification, version II. 2014 Sep 5,;18(5):476.
- <sup>584</sup>(16) Rau C, Wu S, Kuo P, Chen Y, Chien P, Hsieh H, et al. Polytrauma Defined by the New
- 585 Berlin Definition: A Validation Test Based on Propensity-Score Matching Approach. 2017

586 Sep 01, : 14(9).

- <sup>587</sup>(17) Sudhakaran S, McCullough PA. Common laboratory parameters as indicators of
- 588 multi□organ dysfunction in acute heart failure. 2019 Jun;21(6):751-753.
- 589 (18) Bannaga AS, Metzger J, Kyrou I, Voigtländer T, Book T, Melgarejo J, et al. Discovery,

590 validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre

591 study. 2020 Dec 1,;62:103083.

<sup>592</sup>(19) Wendt R, Thijs L, Kalbitz S, Mischak H, Siwy J, Raad J, et al. A urinary peptidomic

593 profile predicts outcome in SARS-CoV-2-infected patients. 2021 Jun 01,;36:100883.

<sup>594</sup>(20) Piedrafita A, Siwy J, Klein J, Akkari A, Amaya-Garrido A, Mebazaa A, et al. A universal

595 predictive and mechanistic urinary peptide signature in acute kidney injury. 2022 Nov <sup>596</sup>7,;26(1):344.

<sup>597</sup>(21) Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A. Novel

598 Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic

- <sup>599</sup>Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. 2018
- 600 Oct 29,;8(1):15940-11.

<sup>601</sup>(22) Verbeke F, Siwy J, Van Biesen W, Mischak H, Pletinck A, Schepers E, et al. The urinary 602 proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients 603 with chronic kidney disease. 2021 Apr 26,;36(5):811-818.



619 Oncol. 2006 Mar;7(3):230-240.

620 (29) Latosinska A, Siwy J, Mischak H, Frantzi M. Peptidomics and proteomics based on 621  $CE \Box MS$  as a robust tool in clinical application: The past, the present, and the future. 2019 622 Sep;40(18-19):2294-2308.

<sup>623</sup>(30) Zürbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, et al. Biomarker 624 discovery by CE-MS enables sequence analysis via MS/MS with platform-independent 625 separation. 2006 Jun 1,;27(11):2111-2125.



- 645 (38) Simona Pozzoli, Marco Simonini, Paolo Manunta. Predicting acute kidney injury: current 646 status and future challenges. 2017 -06-17;31(2):209-223.
- 647 (39) Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur JM, Shaw AD, et al.
- 648 Development and standardization of a furosemide stress test to predict the severity of acute
- 649 kidney injury. 2013;17:1-9.

<sup>650</sup>(40) Koyner JL, Davison DL, Brasha-Mitchell E, Chalikonda DM, Arthur JM, Shaw AD, et al.

651 Furosemide stress test and biomarkers for the prediction of AKI severity. 2015;26(8):2023-

652 2031.

<sup>653</sup>(41) Lu JC, Coca SG, Patel UD, Cantley L, Parikh CR. Searching for genes that matter in

654 acute kidney injury: a systematic review. 2009;4(6):1020-1031.

<sup>655</sup>(42) Emerging concepts in acute kidney injury following cardiac surgery. Seminars in

656 cardiothoracic and vascular anesthesia: SAGE Publications Sage CA: Los Angeles, CA;

657 2008.

<sup>658</sup>(43) Muhamedhussein MS, Manji M, Nungu KS, Ruggajo P, Khalid K. Prevalence and risk

659 factors of acute kidney injury in polytrauma patients at Muhimbili Orthopedic Institute,

<sup>660</sup>Tanzania. 2021 Mar 1,;11(1):74-78.

<sup>661</sup>(44) Ivan MV, Rogobete AF, Bedreag OH, Papurica M, Popovici SE, Dinu A, et al. New

<sup>662</sup>Molecular and Epigenetic Expressions as Novel Biomarkers in Critically Ill Polytrauma

663 Patients with Acute Kidney Injury (AKI). 2018 Jan 1,;64(5):663-668.

<sup>664</sup>(45) Papurica M, Rogobete AF, Cradigati CA, Sarandan M, Dumache R, Bratu LM, et al.

665 Using the Expression of miRNAs as Biomarkers for the Evaluation Acute Respiratory

<sup>666</sup>Distress Syndrome in the Critically Ill Polytrauma Patient. 2016 Jan 1,;62(8):1405-1411.

<sup>667</sup>(46) Cao S, Li H, Xin J, Jin Z, Zhang Z, Li J, et al. Identification of genetic profile and

<sup>668</sup>biomarkers involved in acute respiratory distress syndrome. Intensive Care Med <sup>669</sup>2024;50(1):46-55.

<sup>670</sup>(47) Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al.

671 Acute Respiratory Distress Syndrome: The Berlin Definition. 2012 Jun 20,;307(23):2526-

672 2533.

- <sup>673</sup>(48) Lu S, Huang X, Liu R, Lan Y, Lei Y, Zeng F, et al. Comparison of COVID-19 Induced
- <sup>674</sup>Respiratory Failure and Typical ARDS: Similarities and Differences. 2022 May 27,;9:829771.
- <sup>675</sup>(49) Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does
- $676$  not lead to a "typical" acute respiratory distress syndrome.  $2020;201(10):1299-1300$ .
- <sup>677</sup>(50) Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary
- 678 embolism. 2020;2(2):e200067.
- <sup>679</sup>(51) Maiolo G, Collino F, Vasques F, Rapetti F, Tonetti T, Romitti F, et al. Reclassifying acute
- 680 respiratory distress syndrome. 2018;197(12):1586-1595.
- <sup>681</sup>(52) Maunder RJ, Shuman WP, McHugh JW, Marglin SI, Butler J. Preservation of normal
- 682 lung regions in the adult respiratory distress syndrome: analysis by computed tomography.
- 683 JAMA 1986;255(18):2463-2465.
- <sup>684</sup>(53) Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19
- 685 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med.
- <sup>686</sup>2020;46:1099-1102.
- <sup>687</sup>(54) Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA <sup>688</sup>2020;323(22):2329-2330.
- <sup>689</sup>(55) Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary
- 690 embolism. 2020;2(2):e200067.
- 691 (56) BAKER S, ONEILL B, HADDON W, LONG W. THE INJURY SEVERITY SCORE: A
- 692 METHOD FOR DESCRIBING PATIENTS WITH MULTIPLE INJURIES AND EVALUATING
- <sup>693</sup>EMERGENCY CARE. 1974 Mar;14(3):187-196.
- <sup>694</sup>(57) Palmer C. Major trauma and the injury severity score--where should we set the bar?
- 695 Annu.Proc.Assoc.Adv.Automot Med. 2007;51:13-29.

- <sup>696</sup>(58) Waydhas C, Nast-Kolb D, Trupka A, Kerim-Sade C, Kanz G, Zoller J, et al. Trauma
- 697 scores: reproducibility and reliability. 1992 Feb;95(2):67-70.
- 698 (59) Martens DS, Thijs L, Latosinska A, Trenson S, Zhang Z, Wang C, et al. SSRN-
- 699 id3854583.
- <sup>700</sup>(60) Vassar MJ, Lewis FR, Chambers JA, Mullins RJ, O'Brien PE, Weigelt JA, et al.
- 701 Prediction of Outcome in Intensive Care Unit Trauma Patients: A Multicenter Study of Acute
- 702 Physiology and Chronic Health Evaluation (APACHE), Trauma and Injury Severity Score
- 703 (TRISS), and a 24-Hour Intensive Care Unit (ICU) Point System. 1999 Aug;47(2):324-329.
- <sup>704</sup>(61) Markgraf R, Deutschinoff G, Pientka L, Scholten T, Lorenz C. Performance of the score
- 705 systems Acute Physiology and Chronic Health Evaluation II and III at an interdisciplinary
- 706 intensive care unit, after customization. 2001 Jan 1,;5(1):31-36.

## <sup>708</sup>**Supplementary Data**

- <sup>709</sup>*Supplementary Table 1: Frequencies of injuries and events in the 14 polytrauma patients in the*
- <sup>710</sup>*cohort during the 14-day monitoring period*



728

<sup>729</sup>*Supplementary Table 2: Frequencies of successful sample collection, score and blood* 

<sup>730</sup>*sample trends during the monitoring period of 14 days* 



<sup>732</sup>*Supplementary Table 3: Urinary peptides significantly different in abundance between* 

<sup>733</sup>*healthy controls and trauma patients (N=16 each) (.xls)*